Characteristics of included studies
The search of the four databases yielded 4316 titles, while the grey literature search provided additional 24 research titles. Two thousand, four hundred and forty (2440) titles were remaining after the removal of duplicates; 2410 titles were ineligible and screened out at the abstract stage. Thirty (30) full text articles were screened, out of which 21 were excluded (Appendix 2).
Nine observational studies involving 7,222 participants were included in this review. Included studies (three cohort15-17, five cross sectional18-22 and one case series23) were published between 2003 and 2019 in Australia, Canada, and the U.S. Although most of the studies did not report the dosage of MC, two reported MC dosage range of 1.5mg- 2000mg20,21. The participants ranged in age from 34 to 70 years old.
Quality assessment of included studies
One cohort study15 had a serious risk of confounding and did not provide enough information to make an overall risk of bias assessment. The other cohort study16 had a serious risk of bias related to missing data and inadequate measurement of outcomes The third cohort study17, had a serious risk of bias for confounding and measurement of outcomes, and critical risk of bias related to missing data, with an overall critical risk of bias assessment.
A complete assessment of the risk of bias for the five included cross-sectional studies is presented in Appendix 3. One study18 had no clear study objectives and three18,20,21, had poor outcome measurement. Also, it was unclear what was used to determine statistical significance or precision estimates for the studies18,20,21. In two of the studies18,21, the research methods were insufficiently described to facilitate possible replication. Two others20,21 had funding sources or conflicts of interest that might affect authors’ interpretation of the results. These studies contributed 30% (2333/7222) of participants in the systematic review.
MC use and reduction of opioids dosage
Among a cohort of 35 MC users in the cannabis program of New Hampshire or Vermont, U.S.., there was reduction in mean daily opioid usage of 126.6mg, compared to 138.5mg in those not on the program15. In the same population, there was also reduction in mean emergency department visits and hospital admissions from chronic pain in the preceding calendar year15. Furthermore, in 37 habitual opioid users for chronic pain enrolled in the medical cannabis program, patients on MC were more likely to reduce daily opioid dosage than those not using MC (83.8% vs. 44.8%) over a 21-month period16. A cohort study, with a 4-year follow up period, reported an occasional or regular reduction of opioid use with MC in 22% and 30% of participants on the 3rd and 4th year follow-up waves, respectively17. In a cross-sectional online survey of 1513 members of dispensaries in New England, U.S.A., 76.7% of patients with non-cancer chronic pain using opioids reduced opioid use after starting MC22. Similarly, a sample of 244 MC patients with non-cancer chronic pain attending a Michigan MC dispensary reported a 64% reduction in opioid use after starting MC18, and 18.4% of 2032 Canadian MC patients reported up to a 75% reduction in opioid dosage20. In a case series of three patients with non-cancer chronic pain of 6-10 years duration, the use of MC led to 60-100% reduction in the opioid dosage compared to when MC was not used23. Among 1514 respondents who used MC for non-cancer chronic pain in Australia, there was an average of 70% pain relief, where 100% meant complete pain relief19.
MC use and opioid substitution
Three of the included studies reported an outright substitution of opioids with MC in patients with non-cancer chronic pain16,20,21. There was opioid substitution with MC in 40.5% of MC users compared to 3.4% in non-users16. Amongst MC users in a Canadian MC program, opioid medications accounted for 35.3% (610/1730) of all prescription drug substitutions20, with 32% (80/251)21 and 59.3% (362/610)20 of participants using MC for non-cancer chronic pain reporting an outright stoppage of opioids.